Page last updated: 2024-11-13

rubusoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rubusoside: from RUBUS [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rubusoside : A steviol glycoside that is steviol in which both the carboxy group and the tertiary allylic hydroxy group have been converted to their corresponding beta-D-glucosides. A precious bioactive natural sweetener which mainly exists the in Chinese sweet tea plant, Rubus suavissimus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
RubusgenusA plant genus of the family Rosaceae whose members include blackberries and raspberries.[MeSH]RosaceaeThe rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]

Cross-References

ID SourceID
PubMed CID24721373
CHEMBL ID499256
CHEBI ID145021
SCHEMBL ID12857253
MeSH IDM0157669

Synonyms (23)

Synonym
64849-39-4
rubusoside
1-o-[(5|a,9|a,10|a,13|a)-13-(|a-d-glucopyranosyloxy)-18-oxokaur-16-en-18-yl]-|a-d-glucopyranose
CHEMBL499256
1-o-[13alpha-(beta-d-glucopyranosyloxy)-18-oxo-5beta,8alpha,9beta,10alpha-kaur-16-en-18-yl]-beta-d-glucopyranose
CHEBI:145021
S9130
unii-tcv5k3m3gx
kaur-16-en-18-oic acid, 13-(beta-d-glucopyranosyloxy)-, beta-d-glucopyranosyl ester, (4alpha)-
tcv5k3m3gx ,
rubusoside [inci]
kaur-16-en-18-oic acid, 13-(.beta.-d-glucopyranosyloxy)-, .beta.-d-glucopyranosyl ester, (4.alpha.)-
SCHEMBL12857253
Q-100743
CS-5805
HY-N0668
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1r,4s,5r,9s,10r,13s)-5,9-dimethyl-14-methylidene-13-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
1-o-[(8alpha,9beta,10alpha,13alpha)-13-(beta-d-glucopyranosyloxy)-18-oxokaur-16-en-18-yl]-beta-d-glucopyranose
CCG-270322
Q27289906
BS-42210
(4alpha)-13-(beta-d-glucopyranosyloxy)kaur-16-en-18-oic acid beta-d-glucopyranosyl ester
AKOS040757694

Research Excerpts

Overview

Rubusoside (RUB) is a major ingredient in the leaves of Rubus suavissimus S. It was discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including anticancer compounds.

ExcerptReferenceRelevance
"Rubusoside is a natural sweetener and the active component of "(
Fan, L; Jiang, M; Li, L; Li, Y; Qu, X; Su, J, 2020
)
2
"Rubusoside (RUB) is a major ingredient in the leaves of Rubus suavissimus S."( Metabolomics analysis of the protective effect of rubusoside on palmitic acid-induced lipotoxicity in INS-1 cells using UPLC-Q/TOF MS.
Huang, H; Li, W; Meng, C; Su, Z; Wei, T; Wu, J; Zheng, H, 2019
)
1.49
"Rubusoside (Ru) is a sweetener component in herbal tea and was discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including anticancer compounds."( Production of rubusoside from stevioside by using a thermostable lactase from Thermus thermophilus and solubility enhancement of liquiritin and teniposide.
Jung, SJ; Kang, HK; Kim, D; Kim, M; Kim, YM; Moon, YH; Nguyen, TT, 2014
)
1.48
"rubusoside is a prototype sweet substance isolated from the leaves of the plant Rubrus suavissimus S."( Cariogenicity features of Streptococcus mutans in presence of rubusoside.
Chu, J; He, K; Zhang, T, 2016
)
1.4
"Rubusoside (R) is a natural sweetener and a solubilizing agent with antiangiogenic and antiallergic properties. "( Mass production of rubusoside using a novel stevioside-specific β-glucosidase from Aspergillus aculeatus.
Jeong, HJ; Kim, D; Kim, JS; Kim, YM; Ko, JA; Lee, WS; Park, SJ; Park, TS; Ryu, YB; Wee, YJ, 2012
)
2.15

Toxicity

ExcerptReferenceRelevance
" Current anti-diabetic drugs that protect islet cells are often toxic to healthy cells, resulting in negative side effects."( Metabolomics analysis of the protective effect of rubusoside on palmitic acid-induced lipotoxicity in INS-1 cells using UPLC-Q/TOF MS.
Huang, H; Li, W; Meng, C; Su, Z; Wei, T; Wu, J; Zheng, H, 2019
)
0.77

Bioavailability

ExcerptReferenceRelevance
" The development of this new solubilized, stable, and biologically active CUR formulation lays the foundation for future bioavailability improvement."( A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity.
Hollingsworth, J; Jeansonne, DP; Koh, GY; Liu, Z; Russo, PS; Stout, RW; Vicente, G; Zhang, F, 2011
)
0.37
" About 40% of drugs are not soluble in water in practice and therefore are slowly absorbed, which results in insufficient and uneven bioavailability and GI toxicity."( Production of rubusoside from stevioside by using a thermostable lactase from Thermus thermophilus and solubility enhancement of liquiritin and teniposide.
Jung, SJ; Kang, HK; Kim, D; Kim, M; Kim, YM; Moon, YH; Nguyen, TT, 2014
)
0.76
" These chemical and biological properties demonstrated by the PTX-RUB nanoparticles may improve oral bioavailability and enable further pharmacokinetic, toxicologic, and efficacy investigations."( Cytotoxic and antiangiogenic paclitaxel solubilized and permeation-enhanced by natural product nanoparticles.
Dong, X; Hollingsworth, J; Koh, GY; Liu, Z; Russo, PS; Stout, RW; Yang, P; Zhang, F; Zhang, J, 2015
)
0.42
" Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to the pronounced hydrophobicity of Cer."( Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.
Gu, X; Hill, RA; Hosain, SB; Khiste, SK; Liu, YY; Liu, Z; Nazzal, S; Roy, KR; Uddin, MB, 2020
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
sweetening agentSubstance that sweeten food, beverages, medications, etc.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
tetracyclic diterpenoidA diterpenoid with a tetracyclic skeleton.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
steviol glycosideA diterpene glycoside derived from steviol by formal esterification of the carboxy group with glucose (or a glucose derivative) and glycosylation of the tertiary hydroxy group with combinations of glucose and rhamnose to give the corresponding glycosides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID348194Cytotoxicity against human Raji cells assessed as cell viability at 100 mol ratio by trypan blue staining2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID348190Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 mol ratio after 48hrs by indirect immunofluorescence technique relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151324Antimicrobial activity against Mycobacterium intracellulare ATCC 230682014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID1151318Antimicrobial activity against Candida albicans ATCC 900282014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348187Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 mol ratio after 48hrs by indirect immunofluorescence technique relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151322Antimicrobial activity against Escherichia coli ATCC 352182014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348191Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48hrs by indirect immunofluorescence technique2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151323Antimicrobial activity against Pseudomonas aeruginosa ATCC 278532014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348188Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 mol ratio after 48hrs by indirect immunofluorescence technique relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151319Antimicrobial activity against Cryptococcus neoformans ATCC 901132014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348193Cytotoxicity against human Raji cells assessed as cell viability at 500 mol ratio by trypan blue staining2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151321Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 433002014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348189Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 mol ratio after 48hrs by indirect immunofluorescence technique relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID348195Cytotoxicity against human Raji cells assessed as cell viability at 10 mol ratio by trypan blue staining2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
AID1151320Antimicrobial activity against Aspergillus fumigatus ATCC 909062014Journal of natural products, May-23, Volume: 77, Issue:5
Minor diterpene glycosides from the leaves of Stevia rebaudiana.
AID348192Cytotoxicity against human Raji cells assessed as cell viability at 1000 mol ratio by trypan blue staining2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.56)18.7374
1990's2 (5.13)18.2507
2000's4 (10.26)29.6817
2010's20 (51.28)24.3611
2020's12 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.52 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.54 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]